Drug Profile
Docetaxel - BlueLink Pharmaceuticals
Alternative Names: CRLX-301; Docetaxel nanoparticle - Cerulean PharmaLatest Information Update: 18 Dec 2021
Price :
$50
*
At a glance
- Originator Cerulean Pharma
- Developer BlueLink Pharmaceuticals
- Class Antineoplastics; Drug conjugates; Radiopharmaceutical diagnostics; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 08 Oct 2021 Discontinued - Phase-II for Solid tumours (Late-stage disease, Refractory metastatic disease) in Australia (IV)
- 08 Oct 2021 Discontinued - Phase-II for Solid tumours (Late-stage disease, Refractory metastatic disease) in USA (IV)
- 21 Jul 2020 Additional efficacy data from a phase I/II trial in Solid tumours (Late-stage disease; Refractory metastatic disease) presented at the 111th Annual Meeting of the American Association for Cancer Research (AACR-2020)